Ecusson de la République et du canton de Genève


REPUBLIQUE
ET CANTON
DE GENEVE

Changer la couleur des liensDiminuer la taille du texteAugmenter la taille du texteImprimer la page
ge.ch
 
Ge.ch > Why Geneva

Geneva-based Selexis launches biosimilar cell line development program

06/04/2009

Selexis SA, a Swiss-based biotechnology company offering technologies and services for the rapid development of high-performance stable production cell lines announced an expanded offering focusing on the biosimilar market segment. 

Under the new program, Selexis, the world leader of cell line manufacturing, will offer clients the contract development of high producing mammalian cell lines expressing biosimilars, including expanded characterization capabilities. Selexis scientists have already demonstrated, using the Selexis SURE Cell Line DevelopmentSM Platform, the production of biosimilars proteins at levels as much as 50 fold greater than the currently marketed drugs.
Dr. Igor Fisch, President and CEO of Selexis, commented: “We feel it is a very important step towards the creation of a global company offering fully integrated services to our client worldwide by including biosimilar expressing cell lines  Importantly, in support of this new offer, we are also expanding our support of product characterization capabilities which will further enhance the value of this package”.By combining proprietary technologies with know-how on a fully integrated platform, Selexis can provide top performance cell lines in a industry-known and accepted package.
About Biosimilars:Biosimilars or Follow-on biologics are terms used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiry.
About Selexis:Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells. www.selexis.com
This page of content is part of the files of this website. We preserve this content to provide information on historical basis. Therefore it is not updated.